Noxxon Pharma's Competitors, Revenue, Number of Employees, Funding and Acquisitions

NOXXON develops and commercializes drug-based therapeutics for the treatment of cancer.

Noxxon Pharma's headquarters is l...
Read more

Annual Revenue

Employees

Aram Mangasarian's photo - CEO of Noxxon Pharma

CEO

Aram Mangasarian

CEO Approval Rating

87/100

OVERVIEW

Founded:

1997

Headquarters:

BerlinBerlin

Status:

PublicIndependent Company of OtherALNOX

Industry Sector:

Biotechnology

Pharmaceuticals

Top Competitors or Alternatives

Missing a competitor? Contribute!

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Inovio a competitor of Noxxon Pharma?

Want more news like this in your inbox? Get access for free

Competitive Analysis

TOP COMPETITORS OR ALTERNATIVES

BioNTech is one of Noxxon Pharma's top competitors. BioNTech was founded in 2008, and its headquarters is in Mainz, Rhineland-Palatinate. Like Noxxon Pharma, BioNTech also works within the Biotechnology sector. BioNTech has 1,089 more employees than Noxxon Pharma.

Immatics is Noxxon Pharma's #2 rival. Immatics was founded in 2000 in Tuebingen, Baden-Württemberg. Immatics operates in the Biotechnology industry. Immatics generates $47M more revenue than Noxxon Pharma.

Medigene is a top competitor of Noxxon Pharma. Medigene is a Public company that was founded in Martinsried, Bavaria in 1994. Medigene is in the Biotechnology field. Medigene has 112 more employees vs. Noxxon Pharma.

RANK

COMPANY

LEADERSHIP

CEO SCORE

EMPLOYEES

TOTAL FUNDING

REVENUE

Aram Mangasarian

CEO

- -
11
$100.2M
$ < 1M
1

Ugur Sahin

Co-Founder & CEO

98/100
1,100
$1.1B
$57.3M
2

Harpreet Singh

CEO

82/100
172
$256.3M
$47M
3

Dolores J. Schendel

CEO

64/100
123
$251.2M
$12.6M
4

Garo H. Armen

Chairman & CEO

89/100
255
$284.2M
$114.9M
5

J. Joseph Kim

President & CEO

69/100
239
$277.1M
$7.5M
6

Anthony S. Marucci

President & CEO

68/100
205
$64.5M
$4.8M
7

Elias Papatheodorou

CEO

87/100
$49.1M
8

Kenneth J. Mandell

President & CEO

68/100
33
$205K
$7.9M
9

William J. Golden

Chairman & CEO

90/100
35
$32.7M
$7.8M
10

Greg van Wyk

CEO

90/100
6
$10.8M
$ < 1M

Quarterly and Annual Revenue

Coming soon for Noxxon Pharma!

Annual Revenue

Acquisitions

No recent acquisitions found related to Noxxon Pharma

Noxxon Pharma Funding History

Since Noxxon Pharma was founded in 1997, it has participated in 5 rounds of funding. In total Noxxon Pharma has raised $100.2M. Noxxon Pharma's last funding round was on Aug 2019 for a total of $1.1M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Private Placement
Aug 2019
$1.1M
-
Equity
Nov 2018
$7M
-
Series D
May 2010
$40.4M
Grant
Sep 2009
$1.7M

German Federal Ministry of Education and Research (BMBF)

Series C
May 2007
$50M

NGN Capital

Total Funding: $100.2M

Since Noxxon Pharma was founded in 1997, it has participated in 5 rounds of funding. In total Noxxon Pharma has raised $100.2M. Noxxon Pharma's last funding round was on Aug 2019 for a total of $1.1M

Investments

No recent investments found related to Noxxon Pharma

Noxxon Pharma News

September 13, 2019MarketScreener

Dow And S&P 500 Close To Fresh All-time Highs Ahead Of U.S. Retail-sales

(marketscreener.com) By Mark DeCambre and Chris Matthews, MarketWatch U.S. stock indexes on Friday lo... See more »
August 15, 2019MarketScreener

announces completion of EUR 1 million capital increase

(marketscreener.com) NOXXON ANNOUNCES COMPLETION OF €1 MILLION CAPITAL INCREASE Berlin, Germany, Augu... See more »
July 22, 20194-traders

Half-yearly Report on the Liquidity Contract With Invest Securities

(marketscreener.com) Regulatory News: NOXXON Pharma N.V. (Paris:ALNOX) (Euronext Growth Paris: ALNOX)... See more »
July 19, 2019BioPortfolio

NOXXON Raises Amount of 521 K in Its Rights Issue

Adjustment in Clinical Development Timelines and Business Prospects Regulatory News NOXXON Pharma N.V... See more »
June 27, 20194-traders

Results of NOXXON annual general shareholders meeting

(marketscreener.com) RESULTS OF NOXXON ANNUAL GENERAL SHAREHOLDERS MEETING Berlin, Germany, June 27, ... See more »
June 24, 20194-traders

announces leading international pharma to evaluate NOX-A12 in new indication

(marketscreener.com) NOXXON ANNOUNCES LEADING INTERNATIONAL PHARMA TO EVALUATE NOX-A12 IN NEW INDICAT... See more »
May 24, 2019FinanzNachrichten

NOXXON Announces Convocation of the Annual General Meeting of Shareholders

Regulatory News: NOXXON Pharma N.V. (Paris:ALNOX) (Euronext Growth Paris: ALNOX), a biotechnology com... See more »

Noxxon Pharma Press Releases

January 31, 2018StreetInsider

Half-Yearly Report on the Liquidity Contract with Invest Securities

Pursuant to the liquidity contract entrusted to Invest Securities by NOXXON Pharma (Paris: ALNOX), on... See more »
November 22, 2017streetinsider

NOXXON Announces Its Participation in Three European Investor Conferences in November and December 2017

NOXXON Pharma N.V. (Paris: ALNOX) (EuroNext Growth Paris: ALNOX), a biotechnology company focused on ... See more »
July 10, 2017StreetInsider

NOXXON Pharma Announces Prospectus Publication and Share Transfer to the Public Offering Compartment of the Euronext Growth Market

NOXXON Pharma N.V. (Paris: ALNOX) (EuroNext Growth Paris: ALNOX), a biotechnology company, which focu... See more »
February 7, 2017Business Wire

Heart Transplant Rejection - Pipeline Review, H2 2016 - Key Players Are Astellas Pharma Inc, Nekonal Sarl, Noxxon Pharma AG & Pelican Therapeutics - Research and Markets

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Heart Transplant Rej... See more »
February 1, 2017PR-Inside

Noxxon Pharma AG - Product Pipeline Review - 2016

(PR-inside.com) Global Markets Direct's, 'Noxxon Pharma AG - Product Pipeline Review - 2016', provide... See more »
December 1, 2015NEWSWIRE

Choroidal Neovascularization Pipeline Therapeutics Development Review H2 2015

RnRMarketResearch.com Adds "Choroidal Neovascularization - Pipeline Review, H2 2015" which provides a... See more »

Headquarters

Max-Dohrn-Strasse 8-10

Berlin, Berlin10589

49-30-726247-0

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

NOXXON develops and commercializes drug-based therapeutics for the treatment of cancer. Noxxon Pharma was founded in 1997. Noxxon Pharma's headquarters is located in Berlin, Berlin, DE 10589. It has raised 100.2M in 5 rounds. The latest round was in A...

CEO

Noxxon Pharma's CEO, Aram Mangasarian, currently has an approval rating of 87%. Noxxon Pharma's primary competitors are BioNTech, Immatics & Medigene.

Website

noxxon.com

Frequently Asked Questions about Noxxon Pharma

  1. When was Noxxon Pharma founded?

    Noxxon Pharma was founded in 1997
  2. Who is Noxxon Pharma's CEO?

    Noxxon Pharma's CEO is Aram Mangasarian
  3. How much revenue does Noxxon Pharma generate?

    Noxxon Pharma generates $ < 1M in revenue
  4. How much funding does Noxxon Pharma have?

    Noxxon Pharma has historically raised $100.2M in funding
  1. Where is Noxxon Pharma's headquarters?

    Noxxon Pharma's headquarters is in Berlin Berlin, DE
  2. How many employees does Noxxon Pharma have?

    Noxxon Pharma has 11 employees
  3. What sector does Noxxon Pharma operate in?

    Noxxon Pharma is in Biotechnology, Pharmaceuticals
  4. Who are Noxxon Pharma's competitors?

    Noxxon Pharma's top competitors are BioNTech, Immatics, Medigene